Sarah Huffstetler, APRN
Primary Care · Martin, TNNPI 1629517834
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 41.6% of the total.
Across 201 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$350
- Novo Nordisk$338
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$300
- Lilly USA, LLC$222
- Otsuka America Pharmaceutical, Inc.$214
- plus $482 from 13 others
What the payments were for
- Food & beverage$3,264100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 105 | $1,357 |
| Pfizer | 23 | $350 |
| Novo Nordisk | 13 | $338 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $300 |
| Lilly USA, LLC | 15 | $222 |
| Otsuka America Pharmaceutical, Inc. | 11 | $214 |
| AstraZeneca | 6 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Idorsia Pharmaceuticals US Inc | 4 | $57 |
| Exact Sciences | 2 | $39 |
| GSK | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Amgen | 1 | $25 |
| Mirum Pharmaceuticals, Inc. | 1 | $24 |
| Merck | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Boehringer Ingelheim | 1 | $13 |
| Genentech USA, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$125
How this compares
$3,264 in reported general payments places this provider in the 85th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 69 | $117,386 |
| JardianceEmpagliflozin | 96 | $113,373 |
| OzempicSemaglutide | 97 | $100,623 |
| TrulicityDulaglutide | 64 | $83,532 |
| RybelsusSemaglutide | 25 | $35,183 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $34,827 |
| MounjaroTirzepatide | 20 | $31,037 |
| LinzessLinaclotide | 26 | $28,074 |
| FarxigaDapagliflozin Propanediol | 33 | $27,349 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $25,946 |
| EliquisApixaban | 31 | $22,827 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $19,219 |
| JanuviaSitagliptin Phosphate | 12 | $14,493 |
| XareltoRivaroxaban | 16 | $13,908 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $10,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $1,357 | $145,46095 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $338 | $139,405133 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $222 | $114,57084 claims |
| Boehringer IngelheimJardiance | $13 | $113,37396 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $121 | $46,56763 claims |
| GSKTrelegy Ellipta | $37 | $34,82734 claims |
| MerckJanuvia, Janumet | $20 | $25,22724 claims |
| PfizerEliquis | $350 | $22,82731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 primary care providers in Tennessee.
Other primary care in Martin
- Mary SullivanGermantown$115K
- Len GetzMemphis$25K
- Judith CaldwellNashville$18K
- Mara HutchingsNashville$14K
- Reena BhaktaMurfreesboro$12K
- Ryan HartmanNashville$11K
- Martha LemonsBrentwood$11K
- Abigail EubankHendersonville$9K
- Corey ClelandSevierville$9K
- Katie JohnsonClarksville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.